Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1989 Feb 11;298(6670):345–346. doi: 10.1136/bmj.298.6670.345

Rediscovering monoamine oxidase inhibitors.

C Bass 1, R Kerwin 1
PMCID: PMC1835723  PMID: 2493930

Full text

PDF
345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackwell B., Marley E., Price J., Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 Apr;113(497):349–365. doi: 10.1192/bjp.113.497.349. [DOI] [PubMed] [Google Scholar]
  2. Kay D. W., Garside R. F., Fahy T. J. A double-blind trial of phenelzine and amitriptyline in depressed out-patients. A possible differential effect of the drugs on symptoms. Br J Psychiatry. 1973 Jul;123(572):63–67. doi: 10.1192/bjp.123.1.63. [DOI] [PubMed] [Google Scholar]
  3. Liebowitz M. R., Quitkin F. M., Stewart J. W., McGrath P. J., Harrison W. M., Markowitz J. S., Rabkin J. G., Tricamo E., Goetz D. M., Klein D. F. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988 Feb;45(2):129–137. doi: 10.1001/archpsyc.1988.01800260037004. [DOI] [PubMed] [Google Scholar]
  4. Liebowitz M. R., Quitkin F. M., Stewart J. W., McGrath P. J., Harrison W., Rabkin J., Tricamo E., Markowitz J. S., Klein D. F. Phenelzine v imipramine in atypical depression. A preliminary report. Arch Gen Psychiatry. 1984 Jul;41(7):669–677. doi: 10.1001/archpsyc.1984.01790180039005. [DOI] [PubMed] [Google Scholar]
  5. Pare C. M. The present status of monoamine oxidase inhibitors. Br J Psychiatry. 1985 Jun;146:576–584. doi: 10.1192/bjp.146.6.576. [DOI] [PubMed] [Google Scholar]
  6. Pohl R., Berchou R., Rainey J. M., Jr Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia. J Clin Psychopharmacol. 1982 Dec;2(6):399–407. [PubMed] [Google Scholar]
  7. Quitkin F. M., Stewart J. W., McGrath P. J., Liebowitz M. R., Harrison W. M., Tricamo E., Klein D. F., Rabkin J. G., Markowitz J. S., Wager S. G. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry. 1988 Mar;145(3):306–311. doi: 10.1176/ajp.145.3.306. [DOI] [PubMed] [Google Scholar]
  8. Rabkin J., Quitkin F., Harrison W., Tricamo E., McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol. 1984 Oct;4(5):270–278. [PubMed] [Google Scholar]
  9. Shaw D. M. The practical management of affective disorders. Br J Psychiatry. 1977 May;130:432–451. doi: 10.1192/bjp.130.5.432. [DOI] [PubMed] [Google Scholar]
  10. Sheehan D. V., Ballenger J., Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry. 1980 Jan;37(1):51–59. doi: 10.1001/archpsyc.1980.01780140053006. [DOI] [PubMed] [Google Scholar]
  11. Tyrer P., Candy J., Kelly D. Phenelzine in phobic anxiety: a controlled trial. Psychol Med. 1973 Feb;3(1):120–124. doi: 10.1017/s0033291700046419. [DOI] [PubMed] [Google Scholar]
  12. Tyrer P. Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry. 1976 Apr;128:354–360. doi: 10.1192/bjp.128.4.354. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES